title: Patient preference for monthly bisphosphonate versus weekly bisphosphonate in a cluster-randomized, open-label, crossover trial: Minodroate Alendronate/Risedronate Trial in Osteoporosis (MARTO).
abstract: Minodronate is a potent nitrogen-containing bisphosphonate that can be administered according to a monthly (every 4 weeks) dosing regimen. A 6-month, cluster-randomized, open-label, multicenter, crossover trial was conducted to test the preference of Japanese patients with osteoporosis for monthly bisphosphonate versus weekly bisphosphonate. One hundred and forty-seven patients (postmenopausal women and men) with primary osteoporosis were recruited at eight outpatient clinics. The clinics were randomized into two groups according to the dosing protocol-monthly minodronate followed by weekly alendronate or risedronate for a total of 24 weeks, or weekly alendronate or risedronate followed by monthly minodronate for 24 weeks. Patient preference for either the monthly or weekly bisphosphonate regimen was evaluated using a preference questionnaire. One hundred and fifteen patients (78.2 %) who completed the trial were processed for the analyses. Significantly more patients preferred the monthly bisphosphonate regimen (65.2 %) than the weekly bisphosphonate regimen (15.7 %) (P = 0.007). 'Dosing schedule fits lifestyle better' was the most common reason given for the patient preference for both the monthly (32.0 %) and weekly bisphosphonate (33.3 %) regimens. Significantly more patients found the monthly bisphosphonate regimen to be more convenient (73.0 %) than the weekly bisphosphonate regimen (13.9 %) (P < 0.0001). The safety profiles of the two regimens were similar. The present trial demonstrated a strong patient preference for and the convenience of the monthly bisphosphonate regimen over the weekly bisphosphonate regimen in Japanese patients with osteoporosis.
authors: Institute for Integrated Sports Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo, 160-8582, Japan. jiwamoto@keio.jp.|Department of Orthopaedic Surgery, Keiyu Orthopaedic Hospital, Gunma, 374-0011, Japan. jiwamoto@keio.jp.
authors: Jun
authors: J
authors: Iwamoto
authors: Iidabashi Ladies's Clinic, Tokyo, 102-0072, Japan.
authors: Hiroya
authors: H
authors: Okano
authors: Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, 162-0054, Japan.
authors: Takefumi
authors: T
authors: Furuya
authors: Department of Geriatric Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, 113-0033, Japan.
authors: Tomohiko
authors: T
authors: Urano
authors: Department of Orthopaedic Surgery, Kyorin University School of Medicine, Tokyo, 181-8611, Japan.
authors: Masaichi
authors: M
authors: Hasegawa
authors: Department of Orthopedics, Tokyo Adventist Hospital, Tokyo, 167-8507, Japan.
authors: Hisashi
authors: H
authors: Hirabayashi
authors: Kumakubo Orthopedics Clinic, Tokyo, 165-0025, Japan.
authors: Takami
authors: T
authors: Kumakubo
authors: Makita Obstetrics and Gynecology Clinic, Saitama, 352-0021, Japan.
authors: Kazuya
authors: K
authors: Makita
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D019386:Alendronate / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D018592:Cross-Over Studies; D003710:Demography; D004164:Diphosphonates / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010024:Osteoporosis / Q000188:drug therapy*; D057240:Patient Preference; D000068296:Risedronic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D004164:Diphosphonates; D007093:Imidazoles; C087958:YM 529; D000068296:Risedronic Acid; D019386:Alendronate
keywords: Convenience; Minodronate; Monthly bisphosphonate; Preference; Primary osteoporosis